Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment

Figure 1 Sustained virologic response and measures of adherence among participants with and without mental health disease. A: Sustained virologic response (SVR) achieved (ERADICATE, SYNERGY-A, SPARE). The comparisons of achieved SVR between groups within each study showed no significant differences for those with mental health disease (MHD) from those without MHD; B: Patients with not more than 3 missed doses (ERADICATE, SYNERGY-A, SPARE). The comparisons of adherence tracked by number of patients who had 3 or fewer total missed doses by pill count showed no significant differences for those with MHD from those without MHD in each study; C: Visit adherence (SPARE). Comparisons of total numbers of required visits completed showed no difference between those with MHD and those without during treatment (0-24 wk), through SVR24 (0-48 wk) and overall (P = 0.12); D: GS-331007 concentration at week 2 (SPARE). Comparisons of mean GS-331007 concentration showed no difference between those with MHD and those without at week 2 of treatment (P = 0.72).